The NoA for the US patent application number 11/722,682, entitled ‘Flagellin Related Polypeptides and Uses Thereof,’ covers composition of matter and use of CBLB502 for protecting a mammal from radiation.
Cleveland has also received NoA for the Protectan CBLB612 patent application number 11/917,494, entitled ‘Methods of Protecting against Apoptosis using Lipopeptides.’
It covers the various properties of Protectan CBLB612 and related compounds, including composition of matter and methods of use for protecting against apoptosis.
Cleveland chief operating officer Yakov Kogan said they are pleased to see the patent portfolio protecting their compounds and technology continue to expand in the US and around the world.
"These patents validate our unique approach to protection of healthy tissues from the impact of radiation and other acute stresses," Kogan said.